BOURLA ALBERT 4

What Happened
Albert Bourla, Pfizer’s Chairman & CEO and a director, received a grant of 23 derivative units (reported as an award) on May 29, 2026. The grant is reported at $26.18 per unit for a total reported value of $602. The transaction is coded as an award/grant (A) and represents phantom units rather than actual shares of common stock.

Key Details

• Transaction date: 2026-05-29; filing date: 2026-06-01.
• Award: 23 units @ $26.18 per unit; total reported value $602.
• Shares owned after transaction: Not specified in the provided excerpt.
• Footnote F1: Each unit represents one phantom share of common stock.
• Footnote F2: Units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan; they are cash‑settled following the reporting person's separation from service and may be moved into an alternative investment account at any time.
• Transaction type: Derivative award (phantom units), code A.

Context
This was an award of cash‑settled phantom shares (not a market purchase or sale of common stock). Such deferred compensation grants are common for executives and do not necessarily signal an immediate buy or sell decision; they vest/settle per plan rules and are paid in cash after separation unless moved into the alternative investment account.